title: Oral but not transdermal estrogen replacement therapy reduced level of tissue factor pathway inhibitor: cross-over designed study.
abstract: OBJECTIVE
  The purpose of the present study was to determine changes of biochemical risk factors of thromboembolism especially of TFPI during the use of oral versus transdermal administration of early estrogen replacement therapy.
  
  
  METHODS
  In a 12-week prospective, randomized, cross-over trial, oestradiol was administered orally in a dose of 2 mg daily or transdermally in an equivalent dose of 0.05 mg daily. Forty-five healthy early postmenopausal women were included into the study within 12 weeks after the hysterectomy and ovariectomy (surgical castration). Forty-one women completed the study and their data were analyzed. The average age was of 49+/- 6 years.
  
  
  RESULTS
  After an oral therapy, the average value of TFPI decreased significantly (p < 0.0001) from 87.5 +/- 38.5 ng/ml to 68 +/- 37 ng/ml but remained stable in transdermal group (81.9 +/- 36.8 ng/ml). No significant changes occurred in D-dimers. In both groups AT-III and fibrinogen decreased without exceeding their physiological ranges.
  
  
  CONCLUSIONS
  The oral therapy reduced significantly TFPI levels compared to transdermal route of administration. The results confirm more pronounced impact of oral estrogen on hemostasis variables.
authors.affiliation: Department of Obstetrics and Gynaecology, General Faculty Hospital Prague and 1st Faculty of Medicine, Charles University, Czech Republic. tfait@seznam.cz
authors.forename: Tomas
authors.initials: T
authors.lastname: Fait
authors.forename: Michal
authors.initials: M
authors.lastname: Vrablik
authors.forename: David
authors.initials: D
authors.lastname: Cibula
authors.forename: Jaromir
authors.initials: J
authors.lastname: Masata
authors.forename: Martin
authors.initials: M
authors.lastname: Hill
authors.forename: Bohuslava
authors.initials: B
authors.lastname: Trnkova
mesh_terms: D000279:Administration, Cutaneous; D000284:Administration, Oral; D000328:Adult; D000990:Antithrombin III / Q000032:analysis; D018592:Cross-Over Studies; D004958:Estradiol / Q000008:administration & dosage*; D015914:Estrogen Replacement Therapy / Q000379:methods*; D005260:Female; D005340:Fibrinogen / Q000032:analysis; D006801:Humans; D008074:Lipoproteins / Q000097:blood*; D008875:Middle Aged; D017698:Postmenopause / Q000097:blood / Q000187:drug effects
chemical_list: D008074:Lipoproteins; C068830:antithrombin III Hamilton; C051928:lipoprotein-associated coagulation inhibitor; D004958:Estradiol; D000990:Antithrombin III; D005340:Fibrinogen